

NMSGROUP

ONCOLOGY FORWARD

**NERVIANO
MEDICAL
SCIENCES**

ACCELERA

NERPHARMA

SIMIS

NMS Group S.p.A. names Sidney Shin-Yi Dung as Chief Operating Officer to drive growth

Nerviano, 9 January 2023 NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces the appointment of Ms. Sidney Dung as Chief Operating Officer with immediate effect. Ms. Dung, currently a member of the Company's Executive Leadership Team and Chief of Staff, will take primary responsibility for accelerating groupwise operational performance, continuing the transformation of the business model of each subsidiary and implementing the strategic vision and values of the company, in collaboration with leaders across the firm in her new role as COO.

With over 20 years of experience leading strategic initiatives with cross-functional and multinational teams in manufacturing, transportation, financial services and consultancy sectors with a strong focus in business development, project management and external communications, Ms. Dung joined NMS Group since 2019 to expand her horizon further to the bio-tech sector applying her unique skill set to reinforce the Company's unique value proposition.

"Sidney has deep institutional knowledge of our Company and has been a key driver to our growth," said Hugues Dolgos, Pharm.D., Chief Executive Officer. "She helped established our new vision and, as part of our Executive Leadership Team, she has been instrumental in shaping our strategic priorities and played a key role in the transformation process. Her breadth of skills and focus on execution, along with her diverse background and experience make her the ideal candidate to strengthen the efforts and positive results of the management team and deliver values to all stakeholders. We are thrilled to see the tremendous development of our talented leaders and ready to keep capitalizing on their success going forward."

"I am extremely honored and privileged to be offered the role of Chief Operating Officer and really grateful of the trust and support from the management team and the Board. At this significant turning point of our journey, I look forward to continuously shaping the Company's future development and leading us to the next level of success together with the incredible teams here," said Ms. Dung

###

About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. More than half of our 400 employees are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy.

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera - a preclinical CRO company, and NerPharMa – a CMO/CDMO which manufactures API and drug products supporting clinical developments and commercialization.

Media contact: mediarelations@nmsgroup.it